Switch theme
Sign up to access all valuation multiples
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
2004
235
LTM Revenue $100M
LTM EBITDA -$98.7M
$124M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
UroGen Pharma has a last 12-month revenue (LTM) of $100M and a last 12-month EBITDA of -$98.7M.
In the most recent fiscal year, UroGen Pharma achieved revenue of $90.4M and an EBITDA of -$110M.
UroGen Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See UroGen Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $100M | XXX | $90.4M | XXX | XXX | XXX |
| Gross Profit | $90.0M | XXX | $81.5M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | -$98.7M | XXX | -$110M | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | -122% | XXX | XXX | XXX |
| EBIT | -$103M | XXX | -$96.8M | XXX | XXX | XXX |
| EBIT Margin | -103% | XXX | -107% | XXX | XXX | XXX |
| Net Profit | -$133M | XXX | -$127M | XXX | XXX | XXX |
| Net Margin | -132% | XXX | -140% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, UroGen Pharma's stock price is $4.
UroGen Pharma has current market cap of $195M, and EV of $124M.
See UroGen Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $124M | $195M | XXX | XXX | XXX | XXX | $-2.95 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, UroGen Pharma has market cap of $195M and EV of $124M.
UroGen Pharma's trades at 1.4x EV/Revenue multiple, and -1.1x EV/EBITDA.
Equity research analysts estimate UroGen Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
UroGen Pharma has a P/E ratio of -1.5x.
See valuation multiples for UroGen Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $195M | XXX | $195M | XXX | XXX | XXX |
| EV (current) | $124M | XXX | $124M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | -1.3x | XXX | -1.1x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -1.3x | XXX | XXX | XXX |
| EV/Gross Profit | 1.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.5x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialUroGen Pharma's last 12 month revenue growth is 51%
UroGen Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.8M for the same period.
UroGen Pharma's rule of 40 is -48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
UroGen Pharma's rule of X is 30% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for UroGen Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 51% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Margin | -98% | XXX | -122% | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -48% | XXX | -71% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 197% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
UroGen Pharma acquired XXX companies to date.
Last acquisition by UroGen Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . UroGen Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was UroGen Pharma founded? | UroGen Pharma was founded in 2004. |
| Where is UroGen Pharma headquartered? | UroGen Pharma is headquartered in United States of America. |
| How many employees does UroGen Pharma have? | As of today, UroGen Pharma has 235 employees. |
| Who is the CEO of UroGen Pharma? | UroGen Pharma's CEO is Ms. Elizabeth Barrett. |
| Is UroGen Pharma publicy listed? | Yes, UroGen Pharma is a public company listed on NAS. |
| What is the stock symbol of UroGen Pharma? | UroGen Pharma trades under URGN ticker. |
| When did UroGen Pharma go public? | UroGen Pharma went public in 2017. |
| Who are competitors of UroGen Pharma? | Similar companies to UroGen Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of UroGen Pharma? | UroGen Pharma's current market cap is $195M |
| What is the current revenue of UroGen Pharma? | UroGen Pharma's last 12 months revenue is $100M. |
| What is the current revenue growth of UroGen Pharma? | UroGen Pharma revenue growth (NTM/LTM) is 51%. |
| What is the current EV/Revenue multiple of UroGen Pharma? | Current revenue multiple of UroGen Pharma is 1.2x. |
| Is UroGen Pharma profitable? | Yes, UroGen Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of UroGen Pharma? | UroGen Pharma's last 12 months EBITDA is -$98.7M. |
| What is UroGen Pharma's EBITDA margin? | UroGen Pharma's last 12 months EBITDA margin is -98%. |
| What is the current EV/EBITDA multiple of UroGen Pharma? | Current EBITDA multiple of UroGen Pharma is -1.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
